Organon & Co
OGN
13.79
+0.05
+0.36%
Organon & Co
US · OGN
#2364 by market cap
Listed 1970
13.79
+0.05
+0.36%
Live - 5344 symbols - heartbeat 421s ago
· 2026-10-08 07:40
Pre-market
13.79
0.00%
After-hours
13.79
0.00%
- Market cap
- 3.62B
- P/E (TTM)i
- 17.68
- P/Bi
- 3.60
- EPSi
- 0.72
- Div yieldi
- 0.58%
- 52W posi
- 100%
Reader sentiment
Are you bullish or bearish on OGN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.28, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -2.92% YoY
Margins
- Gross margin
- 53.30%
- Operating margin
- 19.72%
- Net margin
- 3.01%
Key ratios & quality
- Enterprise valuei
- 11.69B
- Altman Z-Scorei
- 1.28
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.78B | 7.78B | 6.53B | 6.30B | 6.17B | 6.26B | 6.40B | 6.22B |
| Gross profit | 5.08B | 5.50B | 4.41B | 3.92B | 3.88B | 3.75B | 3.72B | 3.31B |
| Selling & admin expenses | 2.01B | 1.44B | 1.36B | 1.67B | 1.70B | 1.89B | 1.76B | 1.72B |
| Research & development | 365.00M | 220.00M | 210.00M | 339.00M | 471.00M | 528.00M | 469.00M | 366.00M |
| Operating profit | 2.71B | 3.84B | 2.85B | 1.92B | 1.71B | 1.33B | 1.49B | 1.23B |
| Pretax profit | 2.73B | 3.70B | 2.75B | 1.53B | 1.12B | 673.00M | 807.00M | 425.00M |
| Tax | 576.00M | 390.00M | 496.00M | 178.00M | 205.00M | -350.00M | -57.00M | 238.00M |
| Net profit | 2.15B | 3.22B | 2.16B | 1.35B | 917.00M | 1.02B | 864.00M | 187.00M |
| Basic EPS | 9 | 13 | 9 | 5 | 4 | 4 | 3 | 1 |
| Diluted EPS | 8.51 | 12.71 | 8.53 | 5.31 | 3.59 | 3.99 | 3.33 | 0.72 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.51B | 1.59B | 1.60B | 1.51B | 1.46B | 1.56B |
| Gross profit | 841.00M | 874.00M | 857.00M | 741.00M | 783.00M | 847.00M |
| Selling & admin expenses | 420.00M | 453.00M | 415.00M | 433.00M | 424.00M | 434.00M |
| Research & development | 96.00M | 95.00M | 84.00M | 91.00M | 93.00M | 90.00M |
| Operating profit | 325.00M | 326.00M | 358.00M | 217.00M | 266.00M | 323.00M |
| Pretax profit | 101.00M | 229.00M | 243.00M | -148.00M | 213.00M | 183.00M |
| Tax | 14.00M | 84.00M | 83.00M | 57.00M | 67.00M | 75.00M |
| Net profit | 87.00M | 145.00M | 160.00M | -205.00M | 146.00M | 108.00M |
| Basic EPS | 0 | 1 | 1 | -1 | 1 | 0 |
| Diluted EPS | 0.33 | 0.56 | 0.61 | -0.79 | 0.55 | 0.40 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | -- | 3.96B | 3.57B | 3.76B | 3.93B | 4.51B | 4.35B | 4.35B |
| Cash & ST investments | -- | 319.00M | 12.00M | 737.00M | 706.00M | 693.00M | 675.00M | 574.00M |
| Inventory | -- | 1.07B | 913.00M | 915.00M | 1.00B | 1.32B | 1.32B | 1.41B |
| Total assets | -- | 10.55B | 10.11B | 10.68B | 10.96B | 12.06B | 13.10B | 12.87B |
| Total current liabilities | -- | 1.34B | 2.67B | 2.60B | 2.51B | 2.92B | 2.72B | 2.39B |
| Short-term debt | -- | 34.00M | 1.34B | 9.00M | 8.00M | 9.00M | 20.00M | 16.00M |
| Long-term debt | -- | 70.00M | -- | 9.13B | 8.91B | 8.75B | 8.86B | 8.63B |
| Total liabilities | -- | 3,513,000,000.00 | 4,623,000,000.00 | 12,189,000,000.00 | 11,847,000,000.00 | 12,128,000,000.00 | 12,629,000,000.00 | 12,115,000,000.00 |
| Total equity | -- | 7.04B | 5.49B | -1.51B | -892.00M | -70.00M | 472.00M | 752.00M |
| Retained earnings | -- | 0 | 0 | -998.00M | -331.00M | 443.00M | 1.01B | 1.11B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 4.37B | 4.62B | 4.70B | 4.35B | 4.93B | 5.11B |
| Cash & ST investments | 547.00M | 599.00M | 672.00M | 574.00M | 1.12B | 1.13B |
| Inventory | 1.36B | 1.45B | 1.49B | 1.41B | 1.37B | 1.35B |
| Total assets | 13.16B | 13.50B | 13.55B | 12.87B | 13.00B | 13.18B |
| Total current liabilities | 2.62B | 2.80B | 2.68B | 2.39B | 2.50B | 2.62B |
| Short-term debt | 20.00M | 115.00M | 45.00M | 16.00M | 16.00M | 74.00M |
| Long-term debt | 8.94B | 8.78B | 8.78B | 8.63B | 8.55B | 8.48B |
| Total liabilities | 12,614,000,000.00 | 12,767,000,000.00 | 12,646,000,000.00 | 12,115,000,000.00 | 12,093,000,000.00 | 12,172,000,000.00 |
| Total equity | 542.00M | 733.00M | 906.00M | 752.00M | 903.00M | 1.01B |
| Retained earnings | 1.03B | 1.16B | 1.32B | 1.11B | 1.25B | 1.35B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.69B | 2.77B | 2.19B | 2.46B | 858.00M | 799.00M | 939.00M | 700.00M |
| Depreciation & amortization | 1.67B | 333.00M | 142.00M | 195.00M | 212.00M | 236.00M | 277.00M | 361.00M |
| Free cash flow | 3.59B | 2.68B | 1.93B | 1.97B | 431.00M | 538.00M | 588.00M | 384.00M |
| Dividends paid | -- | 0 | 0 | -145.00M | -290.00M | -294.00M | -297.00M | -88.00M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 244.00M | 319.00M | 12.00M | 737.00M | 706.00M | 693.00M | 675.00M | 574.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 75.00M | 220.00M | 264.00M | 141.00M | 225.00M | 107.00M |
| Depreciation & amortization | 84.00M | 89.00M | 92.00M | 96.00M | 86.00M | 80.00M |
| Free cash flow | -22.00M | 181.00M | 149.00M | 76.00M | 178.00M | 31.00M |
| Dividends paid | -71.00M | -10.00M | -3.00M | -4.00M | -5.00M | -6.00M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 547.00M | 599.00M | 672.00M | 574.00M | 1.12B | 1.13B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | 45.74 | 69.51 | -- | -- | -- | 429.85 | 30.56 |
| ROA %i | -- | 30.51 | 20.59 | 12.80 | 8.48 | 8.89 | 6.87 | 1.44 |
| ROIC %i | -- | 45.08 | 69.51 | -- | -- | -- | 14.13 | 6.24 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 27.68 | 47.52 | 34.33 | 28.35 | 25.01 | 19.16 | 20.72 | 14.95 |
| FCF / sales %i | 36.68 | 34.40 | 23.58 | 31.25 | 6.98 | 8.59 | 9.18 | 6.18 |
| Current ratioi | -- | 2.95 | 1.33 | 1.45 | 1.56 | 1.54 | 1.60 | 1.82 |
| Quick ratioi | -- | 1.35 | 0.39 | 0.82 | 0.87 | 0.84 | 0.75 | 0.80 |
| Debt / assetsi | -- | 0.99 | 13.25 | 85.52 | 81.36 | 72.65 | 67.78 | 67.18 |
| LT debt / equityi | -- | 1.00 | -- | -- | -- | -- | 1,877.12 | 1,147.34 |
| Interest coveragei | -- | -- | -- | 6.93 | 3.66 | 2.28 | 2.55 | 1.84 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -13.61 | -7.41 | -1.39 | 0.52 | 0.23 |
| Net income CAGR (3Y) %i | -- | -- | -- | -14.39 | -34.19 | -22.05 | -13.84 | -41.14 |
| FCF CAGR (3Y) %i | -- | -- | -- | -18.10 | -45.59 | -34.70 | -33.17 | -3.78 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 254.24 | 159.64 | 71.62 | 30.56 | 34.05 | 24.04 |
| ROA %i | 5.99 | 5.46 | 3.81 | 1.44 | 1.88 | 1.57 |
| ROIC %i | 12.65 | 11.99 | 9.15 | 6.24 | 5.70 | 5.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 18.83 | 18.77 | 19.31 | 14.95 | 16.68 | 15.65 |
| FCF / sales %i | 9.31 | 7.67 | 8.98 | 6.18 | 9.48 | 7.08 |
| Current ratioi | 1.67 | 1.65 | 1.75 | 1.82 | 1.97 | 1.95 |
| Quick ratioi | 0.77 | 0.74 | 0.80 | 0.80 | 1.00 | 1.00 |
| Debt / assetsi | 68.08 | 65.90 | 65.14 | 67.18 | 65.94 | 64.90 |
| LT debt / equityi | 1,648.71 | 1,197.95 | 969.43 | 1,147.34 | 947.18 | 842.84 |
| Interest coveragei | 2.31 | 2.30 | 2.36 | 1.84 | 2.09 | 2.05 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Other is the largest reported line at 44.28% of revenue, across 9 reported segments.
- No single line clears half of revenue; Nexplanon/Implanon NXT is next at 14.78%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Other44.28%
Nexplanon/Implanon NXT14.78%
Zetia6.17%
Atozet5.14%
Hadlima5.08%
Other Non-Opioid Pain, Bone and Dermatology5.08%
Arcoxia4.43%
Renflexis4.18%
Follistim AQ3.79%
Quote time 2026-10-08 07:40:25 · For reference only, not investment advice and not tailored to your situation.